Fig. 2: Increased expression of the Ca²⁺ channel component ORAI3 in RA CD4⁺ T cells.

a Transcriptional profiling of Ca²⁺ channel and Ca²⁺ sensor gene transcripts in CD4⁺ naive T cells from HC (n = 6 white bars and circles) and RA (n = 6 gray bars and squares) patients. Gene expression was normalized to β-actin. Data are presented as mean ± SEM. b ORAI3 transcripts quantified by qPCR and normalized to 18S rRNA in CD4⁺ naive T cells from HC (n = 22) and RA (n = 21). Data are shown as dot plots with mean ± SEM. c ORAI3 transcript levels in RA patients with CDAI activity scores <10 (n = 9) or >20 (n = 5). d, e ORAI3 transcripts in CD4⁺ naive T cells from RA patients dichotomized for whether they were treated (n = 5) or not treated with methotrexate (MTX) (n = 16) (d) or whether they were (n = 10) or were not (n = 11) on TNF inhibitors (TNFi, etanercept or adalimumab) (e). f ORAI3 protein levels are shown as a representative immunoblot (left) and as dot plots of densities of ORAI3 relative to β-actin of purified naive CD4⁺ T cells from HC (n = 10) and RA (n = 9) patients. Uncropped Western blots in Supplementary Fig. 9. g ORAI3 transcripts quantified by qPCR and normalized to 18S rRNA in CD4⁺ naive T cells from HC (n = 22) and gout (n = 6), systemic lupus erythematosus (SLE) (n = 7), and PsA (n = 10) patients (HC vs. gout p = 0.80; HC vs. SLE p = 0.85). Statistical analyses were performed with one-way ANOVA followed by Tukey’s multiple comparison test (Fig. 2g) or with unpaired two-tailed Student’s t test (a–f). n.s. not significant. Source data are provided as a Source Data file.